AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24740408 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Group (bevel facing posteriorly)
Number of subjects: 200
Study 24740408 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet‐Portex Group (stylet bent at 60° with Portex tube)
Number of subjects: 200
Study 24740408 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet‐Parker Group (stylet bent at 60° with Parker tube)
Number of subjects: 200
Study 22278741 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin alone (40 mg/day)
Number of subjects: 30
Study 22278741 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin combined therapy (10/20 or 10/40 mg/day)
Number of subjects: 30
Study 22278741 — intervention group
Group type: COMPARATOR
Intervention: All patients (combined group)
Number of subjects: 30
Study 22278741 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 30
Study 20735823 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics (PE) programme
Number of subjects: 19
Study 17635889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 1537) received a telephone counseling program with cooking classes and newsletters promoting dietary targets of 5 vegetable servings, 3 fruit servings, 30 g of fiber, and 15%-20% energy from fat.
Number of subjects: 3088
Study 17635889 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 1551) received print materials describing the '5-A-Day' dietary guidelines.
Number of subjects: 3088
Study 16214920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention
Number of subjects: 87
Study 16214920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 11961679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=1072)
Number of subjects: 1552
Study 11961679 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=480)
Number of subjects: 1552
Study 18370541 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80mg + HCTZ 12.5mg
Number of subjects: 708
Study 18370541 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80mg + HCTZ 25mg
Number of subjects: 708
Study 18370541 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160mg
Number of subjects: 708
Study 18370541 — intervention group
Group type: COMPARATOR
Intervention: valsartan 80mg
Number of subjects: 708
Study 8127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity near-infrared laser radiation (830 nm; 1.5 J/cm2)
Number of subjects: 80
Study 8127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity near-infrared laser radiation (830 nm; 3.0 J/cm2)
Number of subjects: 80
Study 8127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity near-infrared laser radiation (830 nm; 6.0 J/cm2)
Number of subjects: 80
Study 8127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity near-infrared laser radiation (830 nm; 9.0 J/cm2)
Number of subjects: 80
Study 8127206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity near-infrared laser radiation (830 nm; 12 J/cm2)
Number of subjects: 80
Study 8127206 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 80
Study 2511698 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg nitroglycerine patch (70% drug release during the first 12 h)
Number of subjects: 12
Study 2511698 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg nitroglycerine patch (subchronic application)
Number of subjects: 12
Study 2511698 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 12
Study 1103709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone
Number of subjects: 400
Study 1103709 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 400
Study 1103709 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine/Paracetamol
Number of subjects: 400
Study 1103709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 31368382 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBTi (Internet-based cognitive behavioral therapy for insomnia)
Number of subjects: 178
Study 31368382 — intervention group
Group type: COMPARATOR
Intervention: Web-based patient education
Number of subjects: 178
Study 28606961 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity-guided dose reduction (DR)
Number of subjects: 172
Study 28606961 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 172
Study 26850061 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention using text messaging (SMS)
Number of subjects: 1488
Study 26850061 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention using text messaging (SMS) + 45-min nutrition education session
Number of subjects: 1488
Study 26850061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1488
Study 24255998 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional individual, disorder-specific, cognitive-behavioral psychotherapy
Number of subjects: 109
Study 24255998 — intervention group
Group type: COMPARATOR
Intervention: Medication and medical management only (Control)
Number of subjects: 109
Study 21879261 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with cisplatin and 5-fluorouracil (group 1)
Number of subjects: 330
Study 21879261 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with cisplatin and 5-fluorouracil (group 2)
Number of subjects: 330
Study 19597976 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture treatment
Number of subjects: 27
Study 17502802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered to the left dorsolateral prefrontal cortex at a frequency of 10 Hz in 5-second trains at 110% of the estimated prefrontal cortex threshold
Number of subjects: 68
Study 17502802 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 68
Study 14756912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingzhi supplementation (1.44 g Lingzhi/d; equivalent to 13.2 g fresh mushroom/d)
Number of subjects: 18
Study 14756912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 11668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparins with decreasing molecular weights
Number of subjects: 0
Study 11668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparins with longer chains
Number of subjects: 0
Study 11668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparins with higher molecular weight
Number of subjects: 0
Study 10434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 140
Study 10434164 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 140
Study 7792309 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (200 mg daily for 10 days)
Number of subjects: 17
Study 7792309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg twice a day for 10 days)
Number of subjects: 17
Study 7792309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 10 days)
Number of subjects: 17
Study 2193306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 303
Study 2193306 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 303
Study 852810 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate/acetate
Number of subjects: 0
Study 852810 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate/dipropionate
Number of subjects: 0
Study 31607205 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily for 18 months
Number of subjects: 88
Study 31607205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27755256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 250
Study 27755256 — intervention group
Group type: COMPARATOR
Intervention: Nonattenders (Control)
Number of subjects: 250
Study 27755256 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >75 years (Predictor for non-attendance)
Number of subjects: 250
Study 27755256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minorities (Predictor for completion)
Number of subjects: 250
Study 25539895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg daily
Number of subjects: 565
Study 25539895 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg daily
Number of subjects: 565
Study 23590998 — intervention group
Group type: EXPERIMENTAL
Intervention: Female group (F): only female participants
Number of subjects: 251
Study 23590998 — intervention group
Group type: COMPARATOR
Intervention: Standard group (S): male and female participants
Number of subjects: 251
Study 21994128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular fluocinolone acetonide implant
Number of subjects: 0
Study 21994128 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy
Number of subjects: 0
Study 19292785 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA maintenance treatment (irradiation twice weekly and then once weekly for 4 weeks)
Number of subjects: 34
Study 19292785 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 34
Study 19292785 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA maintenance treatment
Number of subjects: 34
Study 17716323 — intervention group
Group type: EXPERIMENTAL
Intervention: Synera patch (lidocaine 70 mg and tetracaine 70 mg, 20-minute treatment)
Number of subjects: 40
Study 17716323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20-minute treatment)
Number of subjects: 40
Study 17716323 — intervention group
Group type: EXPERIMENTAL
Intervention: Synera patch
Number of subjects: 40
Study 17716323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15244013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetraxate plus clarithromycin and amoxicillin (CCA group)
Number of subjects: 58
Study 15244013 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole plus clarithromycin and amoxicillin (PCA group)
Number of subjects: 58
Study 11398691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrically placed feeding tube
Number of subjects: 54
Study 11398691 — intervention group
Group type: COMPARATOR
Intervention: Transpylorically placed feeding tube
Number of subjects: 54
Study 9512152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C
Number of subjects: 197
Study 9512152 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive mitomycin C
Number of subjects: 197
Study 1729932 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg ketamine
Number of subjects: 45
Study 1729932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg ketamine
Number of subjects: 45
Study 1729932 — intervention group
Group type: COMPARATOR
Intervention: No ketamine (control)
Number of subjects: 45
Study 3838120 — intervention group
Group type: EXPERIMENTAL
Intervention: Piloplex (three concentrations)
Number of subjects: 12
Study 3838120 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of the drug
Number of subjects: 12
Study 31854356 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS seven implants
Number of subjects: 17
Study 31854356 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphadent active implants
Number of subjects: 17
Study 30189821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™ laryngeal mask (AG)
Number of subjects: 116
Study 30189821 — intervention group
Group type: COMPARATOR
Intervention: LMA® Fastrach™ (FT)
Number of subjects: 116
Study 26249765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sterile powder for injection (RSPI) 10 mg
Number of subjects: 0
Study 26249765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sterile powder for injection (RSPI) 20 mg
Number of subjects: 0
Study 26249765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sterile powder for injection (RSPI) 40 mg
Number of subjects: 0
Study 26249765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole sterile powder for injection (RSPI) multiple doses 20 mg
Number of subjects: 0
Study 26249765 — intervention group
Group type: COMPARATOR
Intervention: Pariet® 20 mg (control)
Number of subjects: 0
Study 26249765 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RSPI and Pariet®
Number of subjects: 0
Study 22956839 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activity following stimulus encoding
Number of subjects: 0
Study 22956839 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activity preceding the stimulus
Number of subjects: 0
Study 22956839 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent choice history
Number of subjects: 0
Study 22956839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion model fitted to choice probabilities and response time distributions
Number of subjects: 0
Study 22956839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus brain activity
Number of subjects: 0
Study 19454840 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (50/100 microg, 13 patients)
Number of subjects: 27
Study 19454840 — intervention group
Group type: COMPARATOR
Intervention: FP (100 microg, 14 patients)
Number of subjects: 27
Study 17393309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 115
Study 17393309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 115
Study 17393309 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic substitution program (lansoprazole-rabeprazole)
Number of subjects: 115
Study 15380897 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum 299v (ProViva), median volume 3250 ml, median duration 9 days
Number of subjects: 22
Study 15380897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 22
Study 11252881 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute music intervention
Number of subjects: 140
Study 11252881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 140
Study 9673862 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin and etidronate
Number of subjects: 0
Study 9673862 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D metabolites (calcitriol or 1 alpha‐calcidol) and estrogens
Number of subjects: 0
Study 8540748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascoxal (ascorbic acid-containing solution), applied topically 3 times for 2 min on the first day
Number of subjects: 32
Study 8540748 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied topically 3 times for 2 min on the first day
Number of subjects: 32
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. + Indomethacin 50 mg b.i.d.
Number of subjects: 8
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.i.d. + Indomethacin 50 mg b.i.d.
Number of subjects: 8
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 8
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.i.d.
Number of subjects: 8
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. and Enalapril 20 mg o.i.d.
Number of subjects: 8
Study 2551988 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg b.i.d.
Number of subjects: 8
Study 749190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy added to radical mastectomy
Number of subjects: 0
Study 749190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemo- or chemo-hormono-therapy
Number of subjects: 0
Study 749190 — intervention group
Group type: COMPARATOR
Intervention: Local therapy alone (surgery with or without postoperative radiotherapy)
Number of subjects: 0
Study 31889621 — intervention group
Group type: EXPERIMENTAL
Intervention: More equitable gender attitudes
Number of subjects: 866
Study 31889621 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing peers engaged in abusive behaviors (witnessed 3 or more behaviors)
Number of subjects: 866
Study 31175747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness technologies program
Number of subjects: 600
Study 31175747 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational system (Control)
Number of subjects: 600
Study 28816951 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic care (TC)
Number of subjects: 48
Study 28816951 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 48
Study 26111922 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaatsu training (low-load exercise with externally-applied compression) for 3 months
Number of subjects: 0
Study 26111922 — intervention group
Group type: COMPARATOR
Intervention: Center-based, moderate-load resistance training for 3 months
Number of subjects: 0
Study 23233269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin intranasal spray (20 IU twice a day for the first week, then 40 IU twice a day for the following 7 weeks)
Number of subjects: 40
Study 23233269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin intranasal spray
Number of subjects: 40
Study 23233269 — intervention group
Group type: COMPARATOR
Intervention: Placebo intranasal spray (normal saline)
Number of subjects: 40
Study 21644085 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendrick extrication device (KED)
Number of subjects: 60
Study 21644085 — intervention group
Group type: EXPERIMENTAL
Intervention: Long spinal backboard with straps
Number of subjects: 60
Study 18355812 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy on days 11‐13 and 21‐24 of the preceding cycle
Number of subjects: 2
Study 18355812 — intervention group
Group type: COMPARATOR
Intervention: Endometrial biopsy on days 20‐21 of the spontaneous menstrual cycle
Number of subjects: 2
Study 17371175 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS)
Number of subjects: 51
Study 15056124 — intervention group
Group type: EXPERIMENTAL
Intervention: HCA-SX 4667 mg
Number of subjects: 60
Study 15056124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCA-SX 4667 mg, NBC 4 mg, and GSE 400 mg
Number of subjects: 60
Study 15056124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11763951 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g dentifrice containing 0.3% triclosan (3.75 mg triclosan dose) - single-dose phase
Number of subjects: 0
Study 11763951 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times daily brushing with 1.25 g dentifrice containing 0.3% triclosan - multiple-dose phase
Number of subjects: 0
Study 11763951 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily brushing with 1 gm of dentifrice containing 0.2% triclosan
Number of subjects: 0
Study 11763951 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 9574192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic carrier (group 1)
Number of subjects: 324
Study 9574192 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic carrier (group 2)
Number of subjects: 324
Study 9574192 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary wound healing with hydrocolloidal moist wound dressings
Number of subjects: 324
Study 7840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.3 mg/kg bolus + 4 mg/kg/h continuous for 15 min
Number of subjects: 12
Study 7840418 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min
Number of subjects: 12
Study 7840418 — intervention group
Group type: COMPARATOR
Intervention: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min + physostigmine 0.012 mg/kg
Number of subjects: 12
Study 7840418 — intervention group
Group type: COMPARATOR
Intervention: S-(+)-ketamine 0.65 mg/kg bolus + 2 mg/kg/h continuous for 15 min + saline placebo
Number of subjects: 12
Study 3043371 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response training
Number of subjects: 24
Study 3043371 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise
Number of subjects: 24
Study 31188681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning (pure oxygen for 5 minutes)
Number of subjects: 17
Study 31188681 — intervention group
Group type: COMPARATOR
Intervention: Non hyperoxic preconditioning (chamber air for 5 minutes)
Number of subjects: 17
Study 31188681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning
Number of subjects: 17
Study 31188681 — intervention group
Group type: COMPARATOR
Intervention: Non hyperoxic preconditioning
Number of subjects: 17
Study 29050384 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (real)
Number of subjects: 28
Study 29050384 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 28
Study 26235659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklets (n=703)
Number of subjects: 1407
Study 26235659 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet (n=704)
Number of subjects: 1407
Study 23939394 — intervention group
Group type: EXPERIMENTAL
Intervention: CPPED1 knockdown with small interfering RNA
Number of subjects: 0
Study 21749984 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted EBUS (VBNA)
Number of subjects: 199
Study 21749984 — intervention group
Group type: COMPARATOR
Intervention: Non-VBN-assisted EBUS (NVBNA)
Number of subjects: 199
Study 21749984 — intervention group
Group type: COMPARATOR
Intervention: NVBNA
Number of subjects: 199
Study 19491872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery (LARS)
Number of subjects: 1036
Study 16882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centred approach focusing on actual needs
Number of subjects: 100
Study 16882375 — intervention group
Group type: COMPARATOR
Intervention: Current educational activities
Number of subjects: 100